Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-1553 in Combination Therapy for KRAS G12C-mutated NSCLC
CTR20221650Phase 2Completed
- Sponsor
- I-Mab
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of garsorasib in non-small cell lung cancer (NSCLC), sponsored by I-Mab. Started Jul 2022; status: completed.
02
Drugs
garsorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221650.